Claims for Patent: 12,083,270

Summary for Patent: 12,083,270

Title:	Delivery device and method
Abstract:	A nasal delivery device for and method of delivering substance to the middle meatus in a nasal cavity of a subject in the treatment of a condition, in particular an inflammatory or infectious condition, thereof, the delivery device comprising: a nosepiece unit (17) including a nosepiece (20) for fitting to a nostril of a subject and a nozzle (25) through which substance is in use delivered to the respective nasal cavity; and a delivery unit (29) for delivering substance through the nozzle of the nosepiece; wherein the delivery device is configured to provide for deposition of a significant fraction of the delivered dose on, around and in the vicinity of the middle meatus.
Inventor(s):	Per Gisle Djupesland, Roderick Peter Hafner, Colin David Sheldrake
Assignee:	Optinose Inc
Application Number:	US12/279,285
Patent Claims:	1. A method of delivering fluticasone to a middle meatus in a nasal airway of a subject in treatment of rhinosinusitis or nasal polyps in the subject in the need thereof, the method comprising: inserting a nosepiece unit into a first nostril of the subject, the nosepiece unit including a nosepiece and a nozzle through which the fluticasone is delivered to a nasal cavity of the subject from a substance supply unit, which comprises a manually-actuated liquid delivery pump; the subject exhaling through a mouthpiece, which is fluidly connected to the nosepiece, so as to cause closure of an oropharyngeal velum of the subject and deliver an exhalation air flow through the first nostril, around a posterior margin of a nasal septum and out of a second nostril of the subject; and manually actuating the liquid delivery pump to deliver, during exhalation through the mouthpiece, a liquid aerosol spray comprising a dose of fluticasone from the substance supply unit through the nozzle into the cavity; wherein the nosepiece is inserted into the first nostril such that the nosepiece extends into a nasal valve and expands the nasal valve, and the nozzle delivers the dose of fluticasone as at least one liquid jet or liquid aerosol spray having a cone angle of not more than about 50 degrees, whereby at least 50% of the dose of fluticasone as initially deposited in the cavity is deposited in a region of the cavity which is posterior of the nasal valve of the subject and at least 30% of the dose of fluticasone as initially deposited in the cavity is deposited in an upper posterior region of the cavity which is posterior of the nasal valve and above an inferior meatus of the subject. 2. The method of claim 1, wherein the nosepiece is configured to obstruct the nasal valve when the nosepiece is inserted into the first nostril, and thereby prevent deposition of substance anteriorly of the nasal valve. 3. The method of claim 1, wherein at least 55% of the dose as initially deposited in the cavity is deposited in a region posterior of the nasal valve. 4. The method of claim 3, wherein at least 60% of the dose as initially deposited in the cavity is deposited in the region posterior of the nasal valve. 5. The method of claim 4, wherein at least 65% of the dose as initially deposited in the cavity is deposited in the region posterior of the nasal valve. 6. The method of claim 5, wherein at least 70% of the dose as initially deposited in the cavity is deposited in the region posterior of the nasal valve. 7. The method of claim 1, wherein at least 35% of the dose as initially deposited in the cavity is deposited in the upper posterior region thereof. 8. The method of claim 7, wherein at least 40% of the dose as initially deposited in the cavity is deposited in the upper posterior region thereof. 9. The method of claim 8, wherein at least 45% of the dose as initially deposited in the cavity is deposited in the upper posterior region thereof. 10. The method of claim 9, wherein at least 50% of the dose as initially deposited in the cavity is deposited in the upper posterior region thereof. 11. The method of claim 1, wherein the method comprises treating acute rhinosinusitis in the subject in need thereof. 12. The method of claim 1, wherein the method comprises treating chronic rhinosinusitis in the subject in need thereof. 13. The method of claim 1, wherein the nozzle delivers a liquid aerosol spray having a cone angle of not more than about 40 degrees.